to evaluate the effect of 1-deamino-8-d-arginine vasopressin ( ddavp ) in various bleeding disorders , 10 micrograms/m2 ddavp was administered to subjects with von willebrand disease ( 13 ) , platelet function defects ( 12 ) , von willebrand disease and platelet defects together ( 8 ) , or isolated prolongation of the bleeding time ( 5 ) .
C0005779
bleeding disorders
C0042974
von willebrand disease